This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

BIO 2015: The ‘silent killer of innovation’


BIO 2015: The ‘silent killer of innovation’

Rawpixel / Shutterstock.com

Philip Johnson, Johnson & Johnson’s senior vice president of intellectual property and policy, told the BIO International Convention yesterday that uncertainty around patent eligibility of inventions is a “silent killer of innovation”.

BIO 2015, Johnson & Johnson, Sequenom, patent eligibility, diagnostic patents, BIO International Convention 2015, David Kappos


Payment types accepted